Results 261 to 270 of about 2,930,894 (275)

Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy

Clinical and Experimental Immunology, 2012
Stephen Jollès, Rhodri Saunders, J Hagan   +2 more
exaly  

Estrogen replacement therapy in patients with endometrial cancer: a survey of prescription intention of Belgian gynecologists

Ca-A Cancer Journal for Clinicians, 1999
Serge Rozenberg
exaly  

Transmissible of infections by immunoglobulin replacement therapy

Molecular Immunology, 1998
openaire   +1 more source

Development of Standards of Care for Immunoglobulin Replacement Therapy

Journal of Allergy and Clinical Immunology, 2012
C.M. Duff, W. Blouin, D. Sedlak
openaire   +1 more source

NEW DATA ON COMBINED HORMONE REPLACEMENT THERAPY AND BREAST CANCER

Ca-A Cancer Journal for Clinicians, 2003
exaly  

Hormone-replacement therapy and the risk of breast cancer

Ca-A Cancer Journal for Clinicians, 1990
exaly  

Prefilled syringes for immunoglobulin G (IgG) replacement therapy: clinical experience from other disease settings

Expert Opinion on Drug Delivery, 2018
Donald C Vinh
exaly  

Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies

International Journal of Immunopathology and Pharmacology, 2017
Francesco Licciardi, Chiara Azzari, Viviana Moschese   +2 more
exaly  

ESTROGEN/PROGESTIN HORMONE REPLACEMENT THERAPY RISKS OUTWEIGH BENEFITS: STUDY STOPPED EARLY DUE TO EXCESS BREAST CANCER, HEART DISEASE

Ca-A Cancer Journal for Clinicians, 2002
exaly  

LONG-TERM ESTROGEN REPLACEMENT THERAPY MAY INCREASE OVARIAN CANCER RISK

Ca-A Cancer Journal for Clinicians, 2001
exaly